QCG
KRYS icon

Quadrant Capital Group’s Krystal Biotech KRYS Stock Holding History

Quadrant Capital Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-236
Closed -$61K – 1947
2026
Q1 		$61K Buy
236
+80
+51% +$21.3K ﹤0.01% 1635
2025
Q4 		$38.5K Buy
156
+20
+15% +$4.21K ﹤0.01% 1777
2025
Q3 		$24K Buy
+136
New +$20.4K ﹤0.01% 1893
2025
Q2 		– Sell
-3,883
Closed -$700K – 2017
2025
Q1 		$700K Buy
3,883
+3,726
+2,373% +$627K 0.03% 539
2024
Q4 		$24.6K Sell
157
-260
-62% -$46.1K ﹤0.01% 1790
2024
Q3 		$75.9K Buy
417
+343
+464% +$66.1K 0.01% 1233
2024
Q2 		$13.6K Buy
74
+39
+111% +$6.55K ﹤0.01% 2010
2024
Q1 		$6.23K Sell
35
-10
-22% -$1.39K ﹤0.01% 2254
2023
Q4 		$5.58K Buy
45
+10
+29% +$1.11K ﹤0.01% 2247
2023
Q3 		$4.06K Hold
35
– – ﹤0.01% 2225
2023
Q2 		$4.11K Hold
35
– – ﹤0.01% 2251
2023
Q1 		$2.8K Buy
+35
New +$2.75K ﹤0.01% 2365
2022
Q3 		– Sell
-4
Closed – – 2723
2022
Q2 		$0 Hold
4
– – ﹤0.01% 2636
2022
Q1 		$0 Sell
4
-17
-81% -$1.06K ﹤0.01% 2597
2021
Q4 		$1K Buy
+21
New +$1.22K ﹤0.01% 2326

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Quadrant Capital Group's KRYS Position: Q2 2026 in Review

Quadrant Capital Group sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 236 shares — an estimated $61K sold.

Quadrant Capital Group first reported a position in KRYS in Q4 2021 and held it in 15 quarters. The position peaked at $700K in Q1 2025. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Quadrant Capital Group reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 236 Krystal Biotech shares in Q2 2026, an estimated $61K.
  • Quadrant Capital Group first reported a position in Krystal Biotech in Q4 2021 and held it in 15 quarters.
  • Quadrant Capital Group's Krystal Biotech position peaked at $700K in Q1 2025.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.